| Literature DB >> 35390529 |
Claudio G Brunstein1, Paul V O'Donnell2, Brent Logan3, Peter Dawson4, Luciano Costa5, Corey Cutler6, Michael Craig7, William Hogan8, Mary M Horowitz3, Mitchell E Horwitz9, Chatchada Karanes10, John M Magenau11, Adriana Malone12, John McCarty13, Joseph P McGuirk14, Lawrence E Morris15, Andrew R Rezvani16, Rachel Salit17, Sumithira Vasu18, Mary Eapen3, Ephraim J Fuchs19.
Abstract
We previously reported the results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1101, a randomized comparison of hematopoietic cell transplantation (HCT) performed with double umbilical cord blood units (dUCB) or with haploidentical bone marrow (haplo-BMT) with post-transplantation cyclophosphamide (PTCy) in the nonmyeloablative setting. Those results showed similar progression-free survival in the 2 treatment groups but lower nonrelapse mortality and better overall survival in the haplo-BM arm. In this secondary analysis, we sought to investigate whether transplantation center's previous experience with haplo-BM and/or dUCB HCT had an impact on outcomes. All patients randomized in BMT CTN 1101 were included. Center experience was assigned based on the number of transplantations with each platform performed in the year before initiation of the study according to the Center for International Blood and Marrow Transplant Research. Centers were then classified as a dUCB center (>10 dUCB HCTs; n = 117 patients, 10 centers), a haplo-BM center (>10 haplo-BM HCTs and ≤10 dUCB HCTs; n = 110 patients, 2 centers), or other center (≤10 haplo and ≤10 dUCB HCTs; n = 140 patients, 21 centers). After adjusting for age, Karnofsky Performance Status, and Disease Risk Index, we found that haplo-BM centers had lower overall mortality with this donor type compared with dUCB centers (hazard ratio [HR], 2.56; 95% confidence interval [CI], 1.44 to 4.56). In contrast, there were no differences in overall mortality between haplo-BM and dUCB in centers that were experienced with dUCB HCT (HR, 1.02; 95% CI, .59 to 1.79) or had limited to no experience with either dUCB or haplo-BM HCT (HR, 1.36; 95% CI, .83 to 2.21). The higher risk of treatment failure and overall mortality in dUCB HCT in haplo BM-experienced centers was driven by a significantly higher risk of relapse (HR, 1.78; 95% CI, 1.07 to 2.97). With the exception of worse outcomes among dUCB HCT recipients in haplo-BM centers, transplantation center experience in the year before initiation of BMT CTN 1101 had a limited impact on the outcomes of this randomized clinical trial.Entities:
Keywords: Alternative donor transplantation; Cord blood; Haploidentical bone marrow; Transplantation center experience
Mesh：
Year: 2022 PMID： 35390529 PMCID： PMC9253061 DOI： 10.1016/j.jtct.2022.03.024
Source DB: PubMed Journal: Transplant Cell Ther ISSN： 2666-6367